Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 study)

Anticancer Research

Volumn 34, Issue 11, 2014, Pages 6655-6662

  Beppu, Toru ^a   Emi, Yasunori ^b   Tokunaga, Shoji ^c   Oki, Eiji ^d   Shirabe, Ken ^d   Ueno, Shinichi ^e   Kuramoto, Masafumi ^f   Kabashima, Akira ^g   Takahashi, Ikuo ^h   Samura, Hironori ⁱ   Eguchi, Susumu ^j   Akagi, Yoshito ^k   Natsugoe, Shoji ^e   Ogata, Yutaka ^l   Kakeji, Yoshihiro ^m   Baba, Hideo ^a   Maehara, Yoshihiko ^d  

^a KUMAMOTO UNIVERSITY   (Japan)

^b SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e KAGOSHIMA UNIVERSITY   (Japan)

^f Kumamoto General Health Center   (Japan)

^g Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers   (Japan)

^h MATSUYAMA RED CROSS HOSPITAL   (Japan)

ⁱ UNIVERSITY OF THE RYUKYUS   (Japan)

^j NAGASAKI UNIVERSITY   (Japan)

^k KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l KURUME UNIVERSITY MEDICAL CENTER   (Japan)

^m KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Bevacizumab; Chemotherapy; Colorectal liver metastases; Fluorouracil; Hepatic resection; Leucovorin; Oxaliplatin

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL LIVER METASTASIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIVER RESECTION; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; FOLLOW UP; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; SECONDARY; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84916231139     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Takiuchi H, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K and Sugihara K; Japanese Society for Cancer of the Colon and Rectum: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 17: 1-29, 2012.
2. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM and McWilliams RR: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27: 3677-3683, 2009.
3. Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T, Sugihara K, Mochizuki H and Yamamoto J: Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 46: S22-31, 2003.
4. Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, Kunstlinger F, Mentha G, Nordlinger B, Patt Y, Primrose J, Roh M, Rougier P, Ruers T, Schmoll HJ, Valls C, Vauthey NJ, Cornelis M and Kahan JP: OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 23: 7125-7134, 2005.
5. Beppu T, Sakamoto Y, Hasegawa K, Honda G, Tanaka K, Kotera Y, Nitta H, Yoshidome H, Hatano E, Ueno M, Takamura H, Baba H, Kosuge T, Kokudo N, Takahashi K, Endo I, Wakabayashi G, Miyazaki M, Uemoto S, Ohta T, Kikuchi K, Yamaue H, Yamamoto M and Takada T: A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 19: 72-84, 2012.
6. Beppu T, Hayashi N, Masuda T, Komori H, Horino K, Hayashi H, Okabe H, Baba Y, Kinoshita K, Akira C, Watanebe M, Takamori H and Baba H: FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases. Anticancer Res 30: 1015-1020, 2010.
7. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W and Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG): Fédération Francophone de Cancérologie Digestive (FFCD): Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371: 1007-1016, 2008.
8. Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L and Cassidy J: Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 101: 1033-1038, 2009.
9. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F and Saltz L: XELOX vs. FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 105: 58-64, 2011.
10. Japanese Society for Cancer of The colon and Rectum. Japanese Classification of Colorectal Carcinoma. In Second English Edition. Tokyo: Kanehara & Co., Ltd., 2009.
11. Yamaguchi T, Mori T, Takahashi K, Matsumoto H, Miyamoto H and Kato T: A new classification system for liver metastases from colorectal cancer in Japanese multicenter analysis. Hepatogastroenterology 55: 173-178, 2008.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
13. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P: CTCAE c3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181, 2003.
14. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, Mentha G and Terris B: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15: 460-466, 2004.
15. Hirokawa F, Hayashi M, Miyamoto Y, Asakuma M, Shimizu T, Komeda K, Inoue Y and Uchiyama K: Reconsideration of the indications for adjuvant chemotherapy for liver metastases from colorectal cancer after initial hepatectomy. Ann Surg Oncol 2013 Oct 12. [Epub ahead of print]
16. Tsai MS, Su YH, Ho MC, Liang JT, Chen TP, Lai HS and Lee PH: Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol 14: 786-794, 2007.
17. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F and Gruenberger T: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26: 1830-1835, 2008.
18. Beppu T, Miyamoto Y, Sakamoto Y, Imai K, Nitta H, Hayashi H, Chikamoto A, Watanabe M, Ishiko T and Baba H: Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival. Ann Surg Oncol 21: S405-413, 2014.
19. Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L and Choti MA: Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford) 15: 106-115, 2013.
20. Bridgewater J, Adam R, Chau I, Alfonso PG, Rivoire M, Lasserre S, Loeffler M and Gruenberger T: Updated efficacy/safety findings from a randomized, phase? study of bevacizumab plus mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer (OLIVIA study). European Cancer Congress 2013 #2159
21. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F and Köhne CH: Tumour response and secondary resectability of colorectal liver metastases following neoadjavant chemotherapy with cetuximab: the CELIM randomized phase 2 trial. Lancet Oncol 11: 38-47, 2010.
22. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F and Cassidy: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019, 2008.
23. Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, Koelblinger C, Gruenberger B and Gruenberger T: Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 35: 515-20, 2009.
24. Blazer DG 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK and Vauthey JN: Pathologic response to preoperative chemotherapy: a new outcome endpoint after resection of hepatic colorectal metastases. J Clin Oncol 26: 5344-5351, 2008.
25. Wicherts DA, de Haas RJ, Sebagh M, Saenz Corrales E, Gorden DL, Lévi F, Paule B, Azoulay D, Castaing D and Adam R: Bevacizumab was demonstrated to enhance pathological response compared with chemotherapy alone. Br J Surg 98: 399-407, 2011.
26. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, Motta M, Ravarino N, Risio M, Curley SA, Abdalla EK, Capussotti L and Vauthey JN: Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 17: 2870-2876, 2010.
27. Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA and Vauthey JN: Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 30: 4566-4572, 2012.
28. Imai K, Emi Y, Iyama KI, Beppu T, Ogata Y, Kakeji Y, Samura H, Oki E, Akagi Y, Maehara Y, and Baba H: Kyusyu Study Group of Clinical Cancer (KSCC) ancillary study. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Eur J Surg Oncol 40: 559-566, 2014.
29. Schiffer E, Frossard JL, Rubbia-Brandt L, Mentha G and Pastor CM: Hepatic regeneration is decreased in a rat model of sinusoidal obstruction syndrome. J Surg Oncol 99: 439-446, 2009.
30. Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B and Gruenberger T: Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 18: 421-430, 2011.